Melanoma

Drug Name: Opdualag Active Ingredient: nivolumab and relatlimab-rmbw Indications: To treat unresectable or metastatic melanoma Approval Date: 3/18/2022 Company: Bristol-Myers Squibb Company Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf

Drug Name: Kimmtrak Indications: To treat unresectable or metastatic uveal melanoma. Active Ingredient: Tebentafusp-tebn Company: Immunocore Commercial LLC Approval Date: 1/25/2022 More Details: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kimmtrak